Earlier this week, Jaap Goudsmit, Chief Scientist of Leyden Labs, gave a talk on monoclonal antibodies as preventive tools for H5N1 outbreaks, at the global consultation of the World Health Organization (WHO). Anna Beukenhorst, Senior Director of Integrated Data Analytics, moderated a panel discussion on broadly neutralizing antibodies and antivirals. Previously, Leyden Labs showed that intranasal CR9114 protects mice from lethal H5N1 challenge, even at the very low dosage of 4 micrograms (read the article here).

Professor Goudsmit talked about the lessons learned from his 40+ years of experience in research and development of monoclonal antibodies.

Dr Beukenhorst moderated a panel on research and development priorities for monoclonal antibodies and antivirals.

Koenraad Wiedhaup: "We appreciate the effort of the WHO to seek global consultation on this topic. We were happy to share information about our innovative PanFlu program."

Link to meeting information: What research is important to prepare and respond to H5N1 influenza outbreaks?